logo
AdvanceCare Slashes Claims Processing Times to 60 Seconds Using Sprout.ai's AI Technology

AdvanceCare Slashes Claims Processing Times to 60 Seconds Using Sprout.ai's AI Technology

Yahoo5 days ago
LONDON, July 22, 2025 /PRNewswire/ -- AdvanceCare has cut health insurance claims processing time to just 60 seconds for some claims settlement cases, thanks to a strategic rollout of Sprout.ai's artificial intelligence technology. As health insurance claims management continues to grow in complexity, AdvanceCare is using AI to streamline and automate its processes and free up team resources to focus on the most complex cases.
The milestone comes after the health insurer TPA (Third-Party Administrator) processed over a million claims in the past year using Sprout.ai's patented AI platform. AdvanceCare was already operating its claims process with automation, but the integration of Sprout.ai's technology has strengthened its capabilities further, contributing to over a 10% increase in automation levels. These advancements span AdvanceCare's different types of claims including hospital, dental, and pharmacy. With 1.7 million members in Portugal the improvements are already delivering faster, more accurate claim outcomes for a significant portion of the population.
This also comes at a time when healthcare leaders are reporting that the time it takes for claims reimbursement is increasing, with 62% recognising this as a growing challenge, up from 51% in 2022. Sprout.ai's platform allows insurers to make faster, more accurate claims decisions by reducing manual data entry and ensuring claims handlers have all the relevant insights at their fingertips. AdvanceCare benefits from utilising Sprout.ai's platform, which combines advanced artificial intelligence with patented optical character recognition (OCR) technology to instantly extract, structure, and analyse information from claims invoices.
Roi Amir, CEO of Sprout.ai, said: "When it comes to health insurance, speed and accuracy are paramount. This collaboration proves that AI doesn't just improve efficiency — it enhances the customer experience at scale. AdvanceCare has shown what's possible when innovation is embraced across an entire claims ecosystem."
The increased accuracy has led to cost and productivity gains, supporting AdvanceCare's mission to strengthen healthcare inclusion and digital transformation in the insurance sector.
Liliana Silva, Operations Director at AdvanceCare, added: "Our customers highly value the digital reimbursement solution that we provide through our app and web portal. Focusing on efficiency also means focusing on time resolution and the quality of service we provide to our customers. This is why we see AI as a useful tool and look for solutions that contribute to this, such as Sprout.ai."
Since partnering in 2022, Sprout.ai's growing footprint within AdvanceCare highlights the accelerating demand in the European insurtech market for solutions that combine intelligent automation with enhanced service quality — empowering experienced claims handlers to dedicate more time to complex cases and those requiring a human touch.
Logo: https://mma.prnewswire.com/media/2735066/Sprout_Logo.jpg
Notes to editors
For more information on Sprout.ai or to request interview time with CEO, Roi Amir, please contact sproutai@transatlanticent.com.
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/advancecare-slashes-claims-processing-times-to-60-seconds-using-sproutais-ai-technology-302509762.html
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup

Yahoo

time16 minutes ago

  • Yahoo

Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup

Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

Cisco Systems (CSCO): A Steady Performer Among the Dogs of the Dow
Cisco Systems (CSCO): A Steady Performer Among the Dogs of the Dow

Yahoo

time16 minutes ago

  • Yahoo

Cisco Systems (CSCO): A Steady Performer Among the Dogs of the Dow

Cisco Systems, Inc. (NASDAQ:CSCO) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A technician in a laboratory, overseeing cutting edge cybersecurity solutions. Cisco Systems, Inc. (NASDAQ:CSCO) is widely recognized for its networking, cybersecurity, software, and cloud computing solutions. It produces routers and switches that use the Internet Protocol to move data across networks. Artificial intelligence has become a major growth area for Cisco Systems, Inc. (NASDAQ:CSCO), with AI-related revenue exceeding $1 billion in 2024. Cisco aims to at least double that figure in 2025. A key factor in this expansion has been its $28 billion acquisition of Splunk, completed last year, which is intended to strengthen customers' capabilities in networking, security, and AI. Cisco Systems, Inc. (NASDAQ:CSCO) reported strong earnings in its fiscal Q3 2025. The company's revenue came in at $14.15 billion, which showed an 11.4% growth from the same period last year. The revenue also beat analysts' estimates by $91.4 million. Orders for AI infrastructure from webscale clients surpassed $600 million, allowing the company to hit its $1 billion goal a quarter ahead of schedule. This strong performance in AI is driven by the strength of its secure networking solutions, strong global alliances, and the value it consistently delivers to customers. Cisco Systems, Inc. (NASDAQ:CSCO) generated an operating cash flow of $4.1 billion during the quarter, and it returned $1.6 billion to investors through dividends. In addition, it has raised its payouts for 18 consecutive years. Currently, it offers a quarterly dividend of $0.41 per share and has a dividend yield of 2.39%, as of July 26. While we acknowledge the potential of CSCO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store